Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed 40 enrolled Mitchell Cairo

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

Timeline

Start: 2015-05
Primary completion: 2022-06
Completion: 2022-12

Publications

Background Hochberg J, Basso J, Shi Q, Klejmont L, Flower A, Bortfeld K, Harrison L, van de Ven C, Moorthy C, Islam H, Gerard P, Voss S, Cairo MS. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. J Immunother Cancer. 2022 May;10(5):e004445. doi: 10.1136/jitc-2021-004445.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brentuximab Vedotin	Monoclonal antibody	1.2 mg/kg	—
Subject	Doxorubicin	Other / unclassified	25 mg/m2	—
Subject	Rituximab	Monoclonal antibody	375 mg/m2	—
Subject	Vincristine	Small molecule	1.5 mg/m2	—

Brentuximab for Newly Diagnosed Hodgkin Disease

Summary

Timeline

Publications

Drugs

Indications